Quest diagnostics to acquire haystack oncology, adding sensitive liquid biopsy technology for improving personalized cancer care to oncology portfolio

Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined with quest's oncology, genomics and pathology expertise and scale, including solid tumor sequencing, convenient specimen collection and ehr connectivity secaucus, n.j. and baltimore , april 27, 2023 /prnewswire/ -- quest diagnostics (nyse: dgx), the nation's leading provider of diagnostic information services, and haystack oncology, an early-stage oncology company focused on minimal residual disease (mrd) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions, today announced a definitive agreement for quest to acquire haystack in an all-cash equity transaction.
DGX Ratings Summary
DGX Quant Ranking